Bales Scientific FDA Warning Cites Website Promotion Of Unapproved Uses
This article was originally published in The Gray Sheet
Executive Summary
Bales Scientific's website disclaimer that its infrared-emitting pain management system is not approved to treat specific medical conditions is not likely to be deemed acceptable by the FDA, agency staffers maintain, because the site goes on to describe conditions for which the system might be used.
You may also be interested in...
CTI To Own Thermal Imaging Processor Outright Following Bales Acquisition
Computerized Thermal Imaging's acquisition of infrared imaging system manufacturer Bales Scientific includes Bales' thermal imaging processor, an adjunctive diagnostic tool that CTI already uses as part of its own thermal imaging system for breast cancer.
CTI To Own Thermal Imaging Processor Outright Following Bales Acquisition
Computerized Thermal Imaging's acquisition of infrared imaging system manufacturer Bales Scientific includes Bales' thermal imaging processor, an adjunctive diagnostic tool that CTI already uses as part of its own thermal imaging system for breast cancer.
Vysis Improperly Promoting AneuVysion Assay On Website - Warning Letter
Vysis, Inc.' s website improperly promotes the AneuVysion assay as a replacement for standard cytogenic tests to diagnose certain birth defects, FDA says in a Feb. 2 warning letter to the company.